Device Trial Radar · NCT06666790
DermaSensor Postmarket Surveillance Study
Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
396
Planned (sponsor's estimate)
Start
Oct 8, 2024
Primary completion
Apr 11, 2027
Study completion Sep 10, 2027
Sponsor
- Lead sponsor
- DermaSensor, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Single (investigator)
- Primary purpose
- Screening
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
Conditions
- Melanoma, Skin
Interventions
Scan with elastic scattering spectroscopy device to assess risk of malignancyDevice
Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device SensitivityTime frame: 39 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Velocity
New Smyrna Beach, Florida · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.